All of the included clinical trials showed higher long‐term survival rates with immunochemotherapy in advanced ESCC patients compared with chemotherapy alone, when PD‐L1 expression levels were not differentiated. The gene discussed is CD274; the disease is esophageal squamous cell carcinoma.